In conclusion, our findings suggest that pharmacologic inhibition of SREBP2, enzymes required for cholesterol biosynthesis, or the mTOR/Akt signaling pathway, may hold promise for reducing susceptibility to and/or improving outcomes of influenza infection in patients with advanced lung disease and hypercapnia. The gene discussed is SREBF2; the disease is lung disorder.